Serological testing (e.g. The efficacy of Atomoxetine capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see Clinical Studies (14)].
Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
There were no clinical signs or symptoms associated with any reported overdose. Discontinue Aciphex if acute interstitial nephritis develops Published observational studies suggest that PPI therapy like Aciphex may be associated with an increased risk of Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.Several published observational studies in adults suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed in patients treated with Aciphex.Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. The percentages of patients with endoscopic healing are presented below:At Weeks 2 and 4, significantly more patients in the Aciphex 20 and 40 mg groups reported complete resolution of ulcer pain frequency (p≤0.018), daytime pain severity (p≤0.023), and nighttime pain severity (p≤0.035) compared with placebo patients. Atomoxetine, sold under the brand name Strattera, among others, is a medication used to treat attention deficit hyperactivity disorder (ADHD). There were no adverse reactions reported in this study that were not previously observed in adults.The following adverse reactions have been identified during post approval use of rabeprazole. Select one or more newsletters to continue. [7] Patients were confirmed by endoscopy to have no esophageal erosions.The percentage of heartburn free daytime and/or nighttime periods was greater with 20 mg Aciphex delayed-release tablets compared to placebo over the 4 weeks of study in Study RAB-USA-2 (47% vs. 23%) and Study RAB-USA-3 (52% vs. 28%).

Normalization of 24-hour intraesophageal acid exposure was correlated to gastric pH greater than 4 for at least 35% of the 24-hour period; this level was achieved in 90% of subjects receiving Aciphex 20 mg and in 100% of subjects receiving Aciphex 40 mg.  With Aciphex 20 mg and 40 mg per day, significant effects on gastric and esophageal pH were noted after one day of treatment, and more pronounced after seven days of treatment.The median fasting gastrin level increased in a dose-related manner in patients treated once daily with Aciphex delayed-release tablets for up to eight weeks for ulcerative or erosive esophagitis and in patients treated for up to 52 weeks to prevent recurrence of disease. Of the 740 adult patients, 247 (33%) and 241 (33%) patients received 10 mg and 20 mg of Aciphex delayed-release tablets, respectively, while 169 (23%) patients received placebo and 83 (11%) received omeprazole.The safety profile of rabeprazole in the maintenance studies in adults was consistent with what was observed in the acute studies.Less common adverse reactions seen in controlled clinical trials (<2% of patients treated with Aciphex delayed-release tablets and greater than placebo) and for which there is a possibility of a causal relationship to rabeprazole, include the following:  headache, abdominal pain, diarrhea, dry mouth, dizziness, peripheral edema, hepatic enzyme increase, hepatitis, hepatic encephalopathy, myalgia, and arthralgia.No clinically significant laboratory abnormalities particular to the drug combinations were observed.For more information on adverse reactions or laboratory changes with amoxicillin or clarithromycin, refer to their respective prescribing information, In a multicenter, open-label study of adolescent patients 12 to 16 years of age with a clinical diagnosis of symptomatic GERD or endoscopically proven GERD, the adverse event profile was similar to that of adults. Onset of SLE typically occurred within days to years after initiating treatment primarily in patients ranging from young adults to the elderly. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). The related reported adverse reactions that occurred in ≥2% of patients were headache (5.4%) and nausea (1.8%). Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks. The use of Aciphex delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients. Available for Android and iOS devices. Clinical and Laboratory Standards Institute (CLSI). The study was designed to provide at least 80% power to exclude a difference of at least 10% between Aciphex and omeprazole, assuming four-week healing response rates of 93% for both groups.